Prevention of anti-tumor necrosis factor-associated tuberculosis: A 10-year longitudinal cohort study

Clinical Infectious Diseases

Volumn 60, Issue 3, 2015, Pages 349-356

  Munoz, Laura ^a   Casas, Susana ^b   Juanola, Xavier ^a,c   Bordas, Xavier ^a,c   Martinez, Concepcion ^a   Santin, Miguel ^a,c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL DOS DE MAIG   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

anti TNF; IGRAs; latent tuberculosis infection; QuantiFERON TB Gold In Tube; tuberculosis

Indexed keywords

BCG VACCINE; ISONIAZID; RIFAMPICIN; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR;

ADULT; ALTERNATIVE MEDICINE; ANTI TUMOR NECROSIS FACTOR ASSOCIATED TUBERCULOSIS; ANTIMICROBIAL THERAPY; ARTICLE; BCG VACCINATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING TEST; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOUS PLEURISY; ANTAGONISTS AND INHIBITORS; LONGITUDINAL STUDY; MIDDLE AGED; RISK ASSESSMENT;

COHORT STUDIES; FEMALE; HUMANS; LATENT TUBERCULOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RISK ASSESSMENT; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922439124     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu796     Document Type: Article

References (38)

1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104
2. Gomez-Reino JJ, Carmona L, Valverde VR, et al; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-7
3. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-5
4. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society of Rheumatology Biologics Resgister (BSRBR). Ann Rheum Dis 2010; 69: 522-8
5. Harris J, Keane J. How tumor necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010; 161: 1-9
6. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumor necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-206
7. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al; BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-72
8. Gomez-Reino JJ, Carmona L, Descalzo MA; BIOBADASER Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-61
9. Sichleletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006; 10: 1127-32
10. Hsia EC, Cush JJ, Matteson EL, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-Tumor necrosis factor antibody, in phase III clinical trials. Arthritis Care Res (Hoboken) 2013; 65: 309-13
11. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-84
12. Diel R, Goletti D, Ferrara G, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-Analysis. Eur Respir J 2011; 37: 88-99
13. National Institute for Health and Care Excellence. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. NICE Clinical Guideline 117. Available at: www.nice.org.uk/guidance/cg117. Accessed 15 July 2013
14. Tornero J, Sanmarti R, Rodriguez V, et al. Update of the consensus statement of the Spanish society of rheumatology on the management of biological therapies in rheumatoid arthritis. Reumatol Clin 2010; 6: 23-36
15. Fonseca JE, Lucas H, Canhão H, et al. Guidelines for the diagnosis and treatment of latent tuberculosis infection and active tuberculosis in patients with inflammatory joint diseases proposed for treatment with tumor necrosis factor alpha antagonist drugs. Rev Port Pneumol 2006; 12: 603-13
16. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003; 62: 791
17. Diel R, Hauer B, Loddenkemper R, et al. Recommendations for tuberculosis screening before initiation of TNF-Alpha-inhibition treatment in rheumatic diseases. Pneumologie 2009; 63: 329-34
18. Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-Alpha therapy. Swiss Med Wkly 2007; 137: 620-2
19. Nordgaard-Lassen I, Dahlerup JF, Belard E, et al. Guidelines for screening, prophylaxis and critical information prior to initiate anti-TNFalpha treatment. Dan Med J 2012; 59: C4480
20. Winthrop KL. The risk and prevention of tuberculosis: screening strategies to detect latent tuberculosis among rheumatoid arthritis patients who use biologic therapy. Int J Adv Rheumatol 2010; 8: 43-52
21. Winthrop KL, Weinblatt ME, Daley CL. You can't always get what you want, but if you try sometimes (with two tests-TST and IGRA-for tuberculosis) you get what you need. Ann Rheum Dis 2012; 71: 1757-60
22. Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumor necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol 2009; 161: 797-800
23. Scrivo R, Sauzullo I, Mengoni F, et al. Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. Clin Rheumatol 2012; 31: 1567-75
24. Casas S, Andreu A, Juanola X, et al. Diagnosis of tuberculosis infection by tuberculin skin test and a whole-blood interferon-γ release assay in patients considered for anti-Tumor necrosis factor-A therapy. Diagn Microbiol Infect Dis 2011; 71: 57-65
25. Duboczy BO. Practical significance of booster effect of delayed type of skin test. Am Rev Respir Dis 1971; 103: 719-21
26. Hamilton EJ, Jessamine AG, Eidus L. Specificity of the isoniazid drop test for control of domiciliary treatment of tuberculosis. Can Med Assoc J 1964; 90: 695-7
27. Generalitat de Catalunya. Departament de salut. Available at: http://www20. gencat.cat/docs/canalsalut/Home%20Canal%20Salut/Professionals/Temes-de-salut/Tuberculosi/documents/arxius/inf2010tuber.pdf. Accessed 31 January 2014
28. OpenEpi website. Available at: http://www.openepi.com. Accessed 1 February 2014
29. Lowry L. VassarStats; web site for statistical computation. Available at: http://vassarstats.net. Accessed 4 April 2014
30. Scrivo R, Sauzullo I, Mengoni F, et al. The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature. Clin Rheumatol 2014; doi: 10.1007/s10067-014-2669-0
31. Garcovich S, Ruggeri A, D'Agostino M, et al. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-Term anti-TNF-Alpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol 2012; 26: 1572-6
32. Mariette X, Baron G, Tubach F, et al. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic tuberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 2012; 71: 1783-90
33. Chang B, Park HY, Jeon K, et al. Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol 2011; 30: 1535-41
34. Qumseya BJ, Ananthakrishnan AN, Skaros S, et al. QuantiFERON TB Gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis 2011; 17: 77-83
35. Hsia EC, SchlugerN, Cush JJ, et al. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-Tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012; 64: 2068-77
36. Hsia EC, Cush JJ, Matteson EL, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-Tumor necrosis factor antibody, in phase III clinical trials. Arthritis Care Res (Hoboken) 2013; 65: 309-13
37. Zwerling A, Benedetti A, Cojocariu M, et al. Repeat IGRA testing in Canadian health workers: conversions or unexplained variability? PLoS One 2013; 8: e54748
38. Anibarro L, Casas S, Paz-Esquete J, et al. Mycobacteria Study Group (GEIM) of Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. Int J Tuberc Lung Dis 2010; 14: 701-7